213 related articles for article (PubMed ID: 38213169)
1. Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy.
Marvulli R; Lagioia G; Ianieri G; Dell'Olio L; Zonno A; Riccardi M; Sinisi RB; Rizzo LB; Farì G; Megna M; Ranieri M
CNS Neurol Disord Drug Targets; 2024; 23(7):917-926. PubMed ID: 38213169
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy.
Kraus T; Gegenleitner K; Svehlik M; Novak M; Steinwender G; Singer G
Eur J Paediatr Neurol; 2017 May; 21(3):565-569. PubMed ID: 28237420
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury.
Yoon YK; Lee KC; Cho HE; Chae M; Chang JW; Chang WS; Cho SR
Medicine (Baltimore); 2017 Aug; 96(34):e7472. PubMed ID: 28834868
[TBL] [Abstract][Full Text] [Related]
4. The effect of intrathecal baclofen on muscle co-contraction in children with spasticity of cerebral origin.
Sgouros S; Seri S
Pediatr Neurosurg; 2002 Nov; 37(5):225-30. PubMed ID: 12411712
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal baclofen for treating spasticity in children with cerebral palsy.
Hasnat MJ; Rice JE
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD004552. PubMed ID: 26563961
[TBL] [Abstract][Full Text] [Related]
6. [Optimized therapy of spastic syndrome by combination intrathecal baclofen with botulinum toxin].
Vogt T; Urban PP
Nervenarzt; 2000 Dec; 71(12):1007-11. PubMed ID: 11139983
[TBL] [Abstract][Full Text] [Related]
7. [Quality of life in cerebral palsy children treated with intrathecal baclofen pump implantation in parents' opinion].
Borowski A; Pruszczyński B; Miller F; Synder M
Chir Narzadow Ruchu Ortop Pol; 2010; 75(5):318-22. PubMed ID: 21853903
[TBL] [Abstract][Full Text] [Related]
8. Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report.
Santamato A; Panza F; Ranieri M; Amoruso MT; Amoruso L; Frisardi V; Solfrizzi V; Fiore P
J Rehabil Med; 2010 Oct; 42(9):891-4. PubMed ID: 20878052
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study.
Van Schaeybroeck P; Nuttin B; Lagae L; Schrijvers E; Borghgraef C; Feys P
Neurosurgery; 2000 Mar; 46(3):603-9; discussion 609-12. PubMed ID: 10719857
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal baclofen efficacy for managing motor function and spasticity severity in patients with cerebral palsy: a systematic review and meta-analysis.
Masrour M; Zare A; Presedo A; Nabian MH
BMC Neurol; 2024 Apr; 24(1):143. PubMed ID: 38678195
[TBL] [Abstract][Full Text] [Related]
11. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
; Delgado MR; Hirtz D; Aisen M; Ashwal S; Fehlings DL; McLaughlin J; Morrison LA; Shrader MW; Tilton A; Vargus-Adams J
Neurology; 2010 Jan; 74(4):336-43. PubMed ID: 20101040
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.
Saval A; Chiodo AE
J Spinal Cord Med; 2010; 33(1):16-21. PubMed ID: 20397440
[TBL] [Abstract][Full Text] [Related]
13. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin.
Armstrong RW; Steinbok P; Cochrane DD; Kube SD; Fife SE; Farrell K
J Neurosurg; 1997 Sep; 87(3):409-14. PubMed ID: 9285607
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Dai AI; Aksoy SN; Demiryürek AT
J Child Neurol; 2016 Feb; 31(2):184-9. PubMed ID: 25999301
[TBL] [Abstract][Full Text] [Related]
15. Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability.
Charles PD; Gill CE; Taylor HM; Putman MS; Blair CR; Roberts AG; Ayers GD; Konrad PE
Mov Disord; 2010 Mar; 25(4):466-73. PubMed ID: 20131401
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological treatment of spasticity in multiple sclerosis].
Heinzlef O; Monteil-Roch I
Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
[TBL] [Abstract][Full Text] [Related]
17. Use of botulinum toxin A in children with cerebral palsy.
Ross Raftemo AE; Mahendran A; Hollung SJ; Jahnsen RB; Lydersen S; Vik T; Andersen GL
Tidsskr Nor Laegeforen; 2019 May; 139(8):. PubMed ID: 31062563
[TBL] [Abstract][Full Text] [Related]
18. Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study.
Scheinberg A; O'Flaherty S; Chaseling R; Dexter M
J Paediatr Child Health; 2001 Jun; 37(3):283-8. PubMed ID: 11468046
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Dai AI; Wasay M; Awan S
J Child Neurol; 2008 Dec; 23(12):1464-6. PubMed ID: 19073853
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic interventions for reducing spasticity in cerebral palsy.
Patel DR; Soyode O
Indian J Pediatr; 2005 Oct; 72(10):869-72. PubMed ID: 16272661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
